JP2024028454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024028454A5 JP2024028454A5 JP2024002422A JP2024002422A JP2024028454A5 JP 2024028454 A5 JP2024028454 A5 JP 2024028454A5 JP 2024002422 A JP2024002422 A JP 2024002422A JP 2024002422 A JP2024002422 A JP 2024002422A JP 2024028454 A5 JP2024028454 A5 JP 2024028454A5
- Authority
- JP
- Japan
- Prior art keywords
- targeting moiety
- pharmaceutical composition
- recombinant
- limited
- pancreatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862618332P | 2018-01-17 | 2018-01-17 | |
| US62/618,332 | 2018-01-17 | ||
| PCT/US2019/013934 WO2019143767A1 (en) | 2018-01-17 | 2019-01-17 | Methods for treating diabetes, hepatitis, and/or inflammatory liver disease |
| JP2020537722A JP7486423B2 (ja) | 2018-01-17 | 2019-01-17 | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537722A Division JP7486423B2 (ja) | 2018-01-17 | 2019-01-17 | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024028454A JP2024028454A (ja) | 2024-03-04 |
| JP2024028454A5 true JP2024028454A5 (https=) | 2024-07-23 |
Family
ID=65324621
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537722A Active JP7486423B2 (ja) | 2018-01-17 | 2019-01-17 | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 |
| JP2024002422A Pending JP2024028454A (ja) | 2018-01-17 | 2024-01-11 | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537722A Active JP7486423B2 (ja) | 2018-01-17 | 2019-01-17 | 糖尿病、肝炎、および／または炎症性肝疾患を治療するための方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11866488B2 (https=) |
| EP (2) | EP4596042A3 (https=) |
| JP (2) | JP7486423B2 (https=) |
| KR (2) | KR102937161B1 (https=) |
| CN (2) | CN120267797A (https=) |
| AU (2) | AU2019209491B2 (https=) |
| BR (1) | BR112020014346A2 (https=) |
| CA (1) | CA3088661A1 (https=) |
| EA (1) | EA202091533A1 (https=) |
| ES (1) | ES3033317T3 (https=) |
| HR (1) | HRP20250727T1 (https=) |
| HU (1) | HUE072418T2 (https=) |
| IL (2) | IL316486A (https=) |
| MX (1) | MX2020007384A (https=) |
| PH (1) | PH12020551076A1 (https=) |
| PL (1) | PL3740282T3 (https=) |
| RS (1) | RS66918B1 (https=) |
| SG (1) | SG11202006421RA (https=) |
| SM (1) | SMT202500233T1 (https=) |
| WO (1) | WO2019143767A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020234718A1 (en) | 2019-03-13 | 2023-05-18 | Tearsolutions, Inc. | Compositions and methods for promoting islet viability and enhancing insulin secretion |
| EP3999531A1 (en) * | 2019-07-15 | 2022-05-25 | University of Connecticut | Metallothionein antibodies and their use |
| CN110551726B (zh) * | 2019-09-06 | 2021-04-09 | 上海市肺科医院 | 一种结核杆菌阿拉伯半乳聚糖适配子及其应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| KR102191405B1 (ko) * | 2020-09-15 | 2020-12-16 | 주식회사 에이스바이오메드 | 간 질환 예방 또는 치료용 조성물 |
| CN115317502B (zh) * | 2021-12-21 | 2023-07-07 | 青岛市市立医院 | 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用 |
| WO2025226837A1 (en) * | 2024-04-24 | 2025-10-30 | University Of Connecticut | Anti-bacterial metallothionein antibodies and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20030007973A1 (en) | 2001-06-22 | 2003-01-09 | Lynes Michael A. | Methods and compositions for manipulation of the immune response using anti-metallothionein antibody |
| CA2658673A1 (en) | 2005-07-27 | 2008-02-01 | Gerald J. Prud'homme | Composition and method for prevention and treatment of type i and type ii diabetes |
| WO2011050052A2 (en) * | 2009-10-20 | 2011-04-28 | Georgia State University Research Foundation, Inc. | Protein agent for diabetes treatment and beta cell imaging |
| CA2813711A1 (en) | 2010-10-14 | 2012-04-19 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
| CA2840282C (en) | 2011-07-08 | 2018-11-13 | Universiteit Gent | Use of antagonists targeting metallothionein to treat intestinal inflammation |
| WO2014172606A1 (en) * | 2013-04-19 | 2014-10-23 | The Brigham And Women's Hospital, Inc. | Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins |
| TR201402685A1 (tr) | 2014-03-06 | 2015-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vildagliptinin farmasotik formulasyonları. |
| EP3149049B1 (en) * | 2014-05-27 | 2022-10-26 | The University Of Queensland | Il-22 for use in treating metabolic disorders |
| TW201613949A (en) | 2014-08-07 | 2016-04-16 | Regulus Therapeutics Inc | Targeting microRNAs for metabolic disorders |
-
2019
- 2019-01-17 MX MX2020007384A patent/MX2020007384A/es unknown
- 2019-01-17 SG SG11202006421RA patent/SG11202006421RA/en unknown
- 2019-01-17 CA CA3088661A patent/CA3088661A1/en active Pending
- 2019-01-17 RS RS20250601A patent/RS66918B1/sr unknown
- 2019-01-17 KR KR1020207022117A patent/KR102937161B1/ko active Active
- 2019-01-17 JP JP2020537722A patent/JP7486423B2/ja active Active
- 2019-01-17 ES ES19703874T patent/ES3033317T3/es active Active
- 2019-01-17 WO PCT/US2019/013934 patent/WO2019143767A1/en not_active Ceased
- 2019-01-17 HU HUE19703874A patent/HUE072418T2/hu unknown
- 2019-01-17 IL IL316486A patent/IL316486A/en unknown
- 2019-01-17 EA EA202091533A patent/EA202091533A1/ru unknown
- 2019-01-17 SM SM20250233T patent/SMT202500233T1/it unknown
- 2019-01-17 CN CN202510512846.1A patent/CN120267797A/zh active Pending
- 2019-01-17 PL PL19703874.8T patent/PL3740282T3/pl unknown
- 2019-01-17 IL IL276097A patent/IL276097B2/en unknown
- 2019-01-17 US US16/961,327 patent/US11866488B2/en active Active
- 2019-01-17 AU AU2019209491A patent/AU2019209491B2/en active Active
- 2019-01-17 EP EP25158063.5A patent/EP4596042A3/en active Pending
- 2019-01-17 EP EP19703874.8A patent/EP3740282B1/en active Active
- 2019-01-17 KR KR1020267006914A patent/KR20260042289A/ko active Pending
- 2019-01-17 CN CN201980008316.6A patent/CN111801140B/zh active Active
- 2019-01-17 HR HRP20250727TT patent/HRP20250727T1/hr unknown
- 2019-01-17 BR BR112020014346-4A patent/BR112020014346A2/pt unknown
-
2020
- 2020-07-14 PH PH12020551076A patent/PH12020551076A1/en unknown
-
2022
- 2022-08-12 AU AU2022215285A patent/AU2022215285B2/en active Active
-
2023
- 2023-07-24 US US18/357,632 patent/US12583916B2/en active Active
- 2023-10-27 US US18/496,279 patent/US20240067710A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002422A patent/JP2024028454A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024028454A5 (https=) | ||
| TWI641381B (zh) | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 | |
| JP7309606B2 (ja) | 活性比が最適化されたｆｇｆ２１化合物／ｇｌｐ－１ｒアゴニスト組合せ物 | |
| Choe et al. | Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists | |
| CN118480114A (zh) | 胰岛素衍生物 | |
| JP2022180537A (ja) | インスリンアスパルトの安定化された医薬製剤 | |
| KR20210110800A (ko) | 이종성 페이로드의 경구 전달용 콜릭스-유래 담체 | |
| JP2023071827A (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| CN105960249A (zh) | 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂 | |
| JP2016503771A5 (https=) | ||
| JP2016506401A5 (https=) | ||
| CN105899191A (zh) | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 | |
| JP2021511296A5 (https=) | ||
| JP2003524591A (ja) | Ｄｐｉｖ阻害剤のプロドラッグ | |
| US20220152154A1 (en) | Growth differentiation factor 15 combination therapy | |
| JP2025169470A (ja) | Ｇｌｐ－１ｒアゴニスト／ｆｇｆ２１融合タンパク質 | |
| WO2021068986A1 (zh) | 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用 | |
| JP2020518556A5 (https=) | ||
| WO2023066293A1 (en) | Oral delivery of therapeutic agents | |
| US12551541B2 (en) | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | |
| RU2857186C2 (ru) | Рекомбинантный пептид на основе GLP-1, модифицированный по С-концу последовательностью CRAC и обладающий антигипергликемическими свойствами активной формы глюкагоноподобного пептида 1 типа GLP-1 (7-37), и плазмида, обеспечивающая экспрессию рекомбинантного пептида GLP-1 в клетках Е. coli | |
| Bavec | (Poly) peptide-based therapy for diabetes mellitus: Insulins versus incretins | |
| WO2025180387A1 (en) | Super long-lasting glp1 or glp1/gip analogue drugfor type-2 diabetes and obesity | |
| Rho et al. | Diabetes Medications and Cardiovascular Disease Prevention | |
| HK40128194A (zh) | 一种glp1/gdf15双重激动剂 |